GSK plc
GSKNYSECIK 1131399Healthcare
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $bn | 24.7Revenue, FY2021, twelve months to 2021-12-31GBP 24.70bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 29.3Revenue, FY2022, twelve months to 2022-12-31GBP 29.32bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 30.3Revenue, FY2023, twelve months to 2023-12-31GBP 30.33bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-03, accession 0001131399-25-000007.Report this figure | 31.4Revenue, FY2024, twelve months to 2024-12-31GBP 31.38bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 32.7Revenue, FY2025, twelve months to 2025-12-31GBP 32.67bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | |
| Gross margin | % | 66.9%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: GBP 16.53bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2024-03-05, accession 0001131399-24-000007.Revenue: GBP 24.70bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 67.4%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: GBP 19.77bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2025-03-03, accession 0001131399-25-000007.Revenue: GBP 29.32bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 71.8%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: GBP 21.76bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 30.33bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-03, accession 0001131399-25-000007.Report this figure | 71.2%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: GBP 22.33bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 31.38bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 72.4%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: GBP 23.65bn. XBRL concept ifrs-full:GrossProfit. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 32.67bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | |
| Operating margin | % | 17.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: GBP 4.36bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-03-05, accession 0001131399-24-000007.Revenue: GBP 24.70bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 21.9%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: GBP 6.43bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-03-03, accession 0001131399-25-000007.Revenue: GBP 29.32bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 22.2%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: GBP 6.75bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 30.33bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-03, accession 0001131399-25-000007.Report this figure | 12.8%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: GBP 4.02bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 31.38bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 24.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: GBP 7.93bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 32.67bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | |
| Net margin | % | 17.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: GBP 4.38bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2024-03-05, accession 0001131399-24-000007.Revenue: GBP 24.70bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 51.0%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: GBP 14.96bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-03-03, accession 0001131399-25-000007.Revenue: GBP 29.32bn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 16.2%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: GBP 4.93bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 30.33bn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-03, accession 0001131399-25-000007.Report this figure | 8.2%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: GBP 2.58bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 31.38bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 17.5%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: GBP 5.72bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-06, accession 0001131399-26-000004.Revenue: GBP 32.67bn. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | |
| Diluted EPS | $ per share | 1.08Diluted EPS, FY2021, twelve months to 2021-12-31GBP 1.08 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 3.66Diluted EPS, FY2022, twelve months to 2022-12-31GBP 3.66 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-03-03, accession 0001131399-25-000007.Report this figure | 1.20Diluted EPS, FY2023, twelve months to 2023-12-31GBP 1.20 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 0.62Diluted EPS, FY2024, twelve months to 2024-12-31GBP 0.62 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 1.39Diluted EPS, FY2025, twelve months to 2025-12-31GBP 1.39 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | |
| Free cash flow | $bn | 7.0Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: GBP 7.95bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-03-05, accession 0001131399-24-000007.Capital expenditure: GBP 950.0m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-03-05, accession 0001131399-24-000007.Report this figure | 6.3Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: GBP 7.40bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-03-03, accession 0001131399-25-000007.Capital expenditure: GBP 1.14bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-03-03, accession 0001131399-25-000007.Report this figure | 5.5Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: GBP 6.77bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Capital expenditure: GBP 1.31bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 5.2Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: GBP 6.55bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Capital expenditure: GBP 1.40bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure | 6.4Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: GBP 7.74bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Capital expenditure: GBP 1.35bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-06, accession 0001131399-26-000004.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| FMR LLC | 2026-06-30 | $3.41bn | 64,961,641 | Reduced−2,700,005 | |
| Dodge & Cox | 2026-06-30 | $2.53bn | 48,197,514 | Reduced−10,465,460 | |
| Fisher Asset Management, LLC | 2026-06-30 | $1.87bn | 35,722,792 | Added+1,200,429 | |
| PRIMECAP MANAGEMENT CO/CA/ | 2026-06-30 | $1.32bn | 25,182,068 | Reduced−22,470 | |
| WELLINGTON MANAGEMENT GROUP LLP | 2026-06-30 | $597.4m | 11,396,249 | Reduced−321,364 | |
| MORGAN STANLEY | 2026-06-30 | $401.4m | 7,657,562 | Reduced−3,373,089 | |
| ROYAL BANK OF CANADA | 2026-06-30 | $397.8m | 7,588,928 | Added+82,142 | |
| GOLDMAN SACHS GROUP INC | 2026-06-30 | $334.0m | 6,371,442 | Reduced−3,217,672 | |
| STATE STREET CORP | 2026-06-30 | $315.1m | 5,959,115 | Reduced−39,371 | |
| Mondrian Investment Partners LTD | 2026-06-30 | $257.4m | 4,910,830 | Reduced−76,563 |
Recent filings
All 4,469 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2612:16 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-26 | 0001654954-26-009141 |
| 2026-10-2612:05 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-26 | 0001654954-26-009139 |
| 2026-10-2606:51 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-26 | 0001654954-26-009130 |
| 2026-10-2606:32 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-26 | 0001654954-26-009127 |
| 2026-10-2106:14 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-21 | 0001654954-26-009062 |
| 2026-10-1913:06 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-19 | 0001654954-26-009036 |
| 2026-10-1907:25 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-19 | 0001654954-26-009023 |
| 2026-10-1510:47 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-15 | 0001654954-26-008959 |
| 2026-10-1411:42 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-14 | 0001654954-26-008950 |
| 2026-10-1311:12 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-13 | 0001654954-26-008921 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Mar 6, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1131399
- Tickers
- GSK, GLAXF
- Exchange
- NYSE
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- not reported
- Incorporated in
- X0
- Filer category
- Large accelerated filer
- Former names
- GLAXOSMITHKLINE PLC (to 2022-05-16)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 12:18 ET. Listed shows no prices and gives no investment advice.